Stroke Diagnosis Using Polypeptide Biomarker Panels
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current diagnostic methods for stroke lack sensitivity and specificity, and there is a need for non-invasive markers and methods to enable early and accurate diagnosis of stroke, particularly to differentiate between hemorrhagic and ischemic strokes.
Innovation Solution
The use of specific polypeptides such as Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment, and Apo A-I, determined through mass spectrometry and immunoassays, to identify and quantify markers in body fluids, allowing for the diagnosis of stroke and differentiation between hemorrhagic and ischemic strokes.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If S100B is used as a stroke marker, then early detection capability is improved, but sensitivity and specificity are limited to 44% and 67%
Solution Approach 1:
The patent segments the diagnostic approach by using multiple distinct polypeptide markers (H-FABP, B-FABP, ApoA-I, ApoB, ApoC-III, SAA, GFAP) instead of relying on a single marker like S100B. This segmentation allows each marker to contribute to different aspects of stroke detection and differentiation, thereby improving overall sensitivity and specificity while maintaining early detection capability.
Solution Approach 2:
The patent employs a composite diagnostic approach by combining multiple polypeptide markers in a panel-based diagnostic system. This composite strategy integrates the strengths of different markers to achieve both early detection and high reliability, resolving the contradiction between detection capability and diagnostic accuracy.
2Reliability
If multiple polypeptide markers are used to improve diagnostic accuracy, then sensitivity and specificity increase, but device complexity and cost increase
Solution Approach 1:
The patent implements a multi-functional diagnostic system where a single diagnostic platform can detect multiple polypeptide markers simultaneously. This universal approach allows the system to perform both early stroke detection and stroke type differentiation using the same infrastructure, thereby improving sensitivity and specificity without proportionally increasing complexity.
Solution Approach 2:
The patent merges multiple diagnostic functions into a unified test panel that simultaneously measures multiple polypeptide markers. By combining detection of H-FABP, B-FABP, ApoA-I, ApoB, ApoC-III, SAA, and GFAP in a single diagnostic workflow, the system achieves high diagnostic accuracy while streamlining the overall process.
3Ease of operation
If conventional markers are used, then diagnostic method is simple, but ability to differentiate between hemorrhagic and ischemic stroke is insufficient
Solution Approach 1:
The patent applies local quality by assigning specific diagnostic roles to different polypeptide markers based on their differential expression patterns in hemorrhagic versus ischemic stroke. For example, H-FABP and B-FABP serve as early markers for both types, while ApoC-III and SAA provide differentiation capability. This localized functional assignment maintains operational simplicity while achieving precise stroke type differentiation.
Solution Approach 2:
The patent introduces specific polypeptide markers as intermediaries that mediate between the complex pathophysiology of different stroke types and the simplified diagnostic readout. These markers act as biological mediators that translate underlying pathological differences into detectable signal patterns, enabling accurate differentiation without complicating the diagnostic workflow.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach provides a more accurate and early diagnosis of stroke, enabling prompt treatment and differentiation between stroke types, improving patient outcomes by increasing sensitivity and specificity of diagnostic tests.
Implementation Method 1
subjecting a sample of body fluid taken from the subject to mass spectrometry, thereby to determine a test amount of a polypeptide in the sample
Implementation Method 2
the mass spectrometry involves surface-enhanced laser desorption/ionisation (SELDI)
Implementation Method 3
determined through mass spectrometry and immunoassays, to identify and quantify markers in body fluids
Data Source
AI summary
Stroke is diagnosed in a subject by determining the concentration of at least one polypeptide selected from Apo C-III, Serum Amyloid A, Apo C-I, Antithrombin III fragment and Apo A-I in a sample of body fluid taken from the subject.